Porton Bio

Founded in 2018 and located in Suzhou, China, Porton Bio is a subsidiary of the globally recognized CDMO Porton Pharma Solutions Ltd. (SZSE Stock Code 300363). Portonbio offers global biotech companies a seamlessly integrated, cGMP-compliant manufacturing platform spanning from plasmids, viral vectors and cell therapeutics to enable early to late-phase clinical trials and commercial production.

Featuring a world-class senior management team with global experience, Portonbio’s “Customer First” approach to Gene and Cell Therapeutics (GCT) manufacturing is anchored by our core principles of “Compliance, Expertise, Focus and Open Collaboration”. Operating to rigorous, internationally harmonized Quality Management and IP protection standards, Portonbio is bringing innovative and highly flexible development and manufacturing solutions to the complex challenges in the GCT space ‒ ultimately enabling the public’s early access to advanced therapies.